
Treballi amb nosaltres
VHIO, resposta als avanços en recerca oncològica
2010-09-26
The group of Joan Seoane within the Vall d’Hebron Institute of Oncology, Barcelona, is looking for a lab manager fellow. Our main field of interest is the understanding of the molecular mechanisms involved in the genesis and progression of glioma. Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of glioma is essential for the development of successful and rational therapeutic strategies. Our approach is based on a tight collaboration with clinical researchers of the Vall d’Hebron hospital and the study of patient-derived tumours. We analyse human biopsies, generate primary cultures of human tumour cells, isolate the stem-cell-like population of patient-derived gliomas and generate mouse models for glioma based on the orthotopical inoculation of human glioma stem cells in the mouse brain to generate tumours with the same characteristics as the original human tumour. Moreover, we participate in ongoing clinical trials obtaining critical information about the biology of human tumours. We expect that our results will help understand the biology of glioma and cancer, and we aspire to translate our discoveries to a clinical ambit identifying molecular markers of diagnosis and prognosis, markers of response to therapies, and unveil new therapeutic targets against this deadly disease.
2010-09-26
The group of Joan Seoane within the Vall d’Hebron Institute of Oncology, Barcelona, is looking for a post-doctoral research fellow. Our main field of interest is the understanding of the molecular mechanisms involved in the genesis and progression of glioma. Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of glioma is essential for the development of successful and rational therapeutic strategies. Our approach is based on a tight collaboration with clinical researchers of the Vall d’Hebron hospital and the study of patient-derived tumours. We analyse human biopsies, generate primary cultures of human tumour cells, isolate the stem-cell-like population of patient-derived gliomas and generate mouse models for glioma based on the orthotopical inoculation of human glioma stem cells in the mouse brain to generate tumours with the same characteristics as the original human tumour. Moreover, we participate in ongoing clinical trials obtaining critical information about the biology of human tumours. We expect that our results will help understand the biology of glioma and cancer, and we aspire to translate our discoveries to a clinical ambit identifying molecular markers of diagnosis and prognosis, markers of response to therapies, and unveil new therapeutic targets against this deadly disease.
2010-04-02
2010-03-16
Oferim 3 places com a gestor de dades d'assaigs clínics d'oncologia
2010-03-03
S’incorporarà al VHIO per donar recolzament al Departament Econòmic-Financer de la Fundació.
2010-03-03
S’incorporarà al VHIO per donar recolzament al Departament Econòmic-Financer de la Fundació.
2010-01-30
Depenent de la Gerència de la Fundació, les seves tasques seran les de gestionar les infraestructures, instal·lacions, equipament i serveis generals amb l’objectiu de garantir unes òptimes condicions de funcionalitat i seguretat en els espais vinculats a VHIO.
2009-12-15
La
investigació en genòmica és clau per a la caracterització dels tumors,
i tindrà un paper rellevant en la recerca bàsica i clínica del futur, així com en el desenvolupament de fàrmacs contra el càncer.
El Tècnic per al Servei de Genòmica del VHIO proporcionarà genotipat (seqüenciació
amb tecnologia MassARRAY) i seqüenciació d'alt rendiment (Genome
Analyzer II, Illumina) a investigadors bàsics i clínics de
l'Institut. A més, donarem suport als investigadors amb anàlisis bioinformàtiques, personalitzades per a cada projecte individual.
2009-08-20
Responsable de subvencions
2009-08-20
El Laboratori de Models Animals i Càncer de l'Institut de Recerca Vall d'Hebron ofereix diversos llocs de treball per a la investigació en melanoma i oncologia translacional
Si us plau, completa tots els camps obligatoris.
©2008 VALL D’HEBRON. Institut d’Oncologia. Todos los derechos reservados